Alumis Inc. (NASDAQ:ALMS - Get Free Report) has received a consensus recommendation of "Buy" from the eight brokerages that are presently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $26.83.
Several analysts have recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $26.00 price target on shares of Alumis in a research report on Friday, December 20th. Robert W. Baird began coverage on Alumis in a report on Thursday, October 31st. They issued an "outperform" rating and a $25.00 target price for the company. Cantor Fitzgerald restated an "overweight" rating on shares of Alumis in a report on Thursday, November 14th. Finally, Baird R W upgraded Alumis to a "strong-buy" rating in a research note on Thursday, October 31st.
View Our Latest Research Report on ALMS
Hedge Funds Weigh In On Alumis
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. SR One Capital Management LP acquired a new position in shares of Alumis in the 2nd quarter valued at $26,067,000. Charles Schwab Investment Management Inc. acquired a new position in Alumis in the third quarter valued at $1,160,000. Towerview LLC grew its holdings in shares of Alumis by 22.6% during the third quarter. Towerview LLC now owns 380,000 shares of the company's stock worth $4,058,000 after purchasing an additional 70,000 shares during the last quarter. Stifel Financial Corp acquired a new stake in shares of Alumis during the third quarter worth about $931,000. Finally, Samsara BioCapital LLC acquired a new stake in shares of Alumis during the third quarter worth about $34,886,000.
Alumis Stock Up 4.5 %
NASDAQ:ALMS traded up $0.34 during trading hours on Tuesday, hitting $7.86. The company had a trading volume of 104,038 shares, compared to its average volume of 149,901. Alumis has a 1 year low of $7.46 and a 1 year high of $13.53. The business's 50-day moving average price is $9.81.
Alumis Company Profile
(
Get Free ReportOur mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Further Reading
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
